These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17426969)

  • 1. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
    Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV
    Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
    Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
    Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Immunocytokine and
    Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM
    Front Immunol; 2021; 12():668307. PubMed ID: 34489927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
    Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
    PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
    Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.
    Dasgupta A; Shields JE; Spencer HT
    Hum Gene Ther; 2012 Jul; 23(7):711-21. PubMed ID: 22397715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice.
    Sartelet H; Durrieu L; Fontaine F; Nyalendo C; Haddad E
    In Vivo; 2012; 26(1):19-29. PubMed ID: 22210712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
    Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
    Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells.
    Kalberer CP; Siegler U; Wodnar-Filipowicz A
    Blood; 2003 Jul; 102(1):127-35. PubMed ID: 12637322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
    Jiang W; Zhang C; Tian Z; Zhang J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
    Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
    J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
    Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
    Front Immunol; 2019; 10():1262. PubMed ID: 31231387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
    Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.
    Rueda F; Martí F; Pardo N; Badell I; Peiró M; Bertran E; Villén E; García J; Cubells J
    Cancer Biother Radiopharm; 1996 Oct; 11(5):303-8. PubMed ID: 10851509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.
    Miller JS; Rooney CM; Curtsinger J; McElmurry R; McCullar V; Verneris MR; Lapteva N; McKenna D; Wagner JE; Blazar BR; Tolar J
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1252-7. PubMed ID: 24816582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.